Plimoth Trust Co. LLC Takes $486,000 Position in Novo Nordisk A/S (NYSE:NVO)

Plimoth Trust Co. LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,645 shares of the company’s stock, valued at approximately $486,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Natixis Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC raised its position in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares during the period. Versant Capital Management Inc purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at $86,000. Talbot Financial LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at $4,066,000. Finally, Zions Bancorporation N.A. increased its position in shares of Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on NVO. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 0.0 %

Novo Nordisk A/S stock traded down $0.01 during trading hours on Wednesday, reaching $85.18. The company had a trading volume of 686,640 shares, compared to its average volume of 9,496,421. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a 50-day moving average price of $94.75 and a 200 day moving average price of $114.02. The firm has a market cap of $382.25 billion, a price-to-earnings ratio of 27.53, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.